Malin Corporation plc - Asset Resilience Ratio
Malin Corporation plc (MLC) has an Asset Resilience Ratio of 5.49% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Malin Corporation plc (MLC) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2023)
This chart shows how Malin Corporation plc's Asset Resilience Ratio has changed over time. See MLC book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Malin Corporation plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MLC company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €6.40 Million | 5.49% |
| Total Liquid Assets | €6.40 Million | 5.49% |
Asset Resilience Insights
- Limited Liquidity: Malin Corporation plc maintains only 5.49% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Malin Corporation plc Industry Peers by Asset Resilience Ratio
Compare Malin Corporation plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
Annual Asset Resilience Ratio for Malin Corporation plc (2018–2023)
The table below shows the annual Asset Resilience Ratio data for Malin Corporation plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 5.49% | €6.40 Million ≈ $7.48 Million |
€116.60 Million ≈ $136.32 Million |
+5.06pp |
| 2020-12-31 | 0.43% | €1.60 Million ≈ $1.87 Million |
€370.60 Million ≈ $433.27 Million |
+0.09pp |
| 2018-12-31 | 0.34% | €900.00K ≈ $1.05 Million |
€264.40 Million ≈ $309.11 Million |
-- |
About Malin Corporation plc
Malin Corporation plc, through its subsidiaries, operates in the life sciences industry in Ireland and the United States. It also engages in investment activities. The company was incorporated in 2014 and is headquartered in Dublin, Ireland.